Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$38.80 +1.2%	$33.14	$23.23 ▼ $42.29	$1.22B	0.68	368,564 shs	516,011 shs
CVAC CureVac	$5.37	$5.43	$2.37 ▼ $5.72	$1.20B	2.53	935,476 shs	321,215 shs
DRUG Bright Minds Biosciences	$38.88 -8.8%	$32.90	$0.94 ▼ $79.02	$273.72M	-6.07	49,206 shs	29,435 shs
ELVN Enliven Therapeutics	$20.27 -0.4%	$20.47	$13.30 ▼ $30.03	$1.20B	0.93	375,349 shs	589,226 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	-1.13%	-2.96%	+22.88%	+30.49%	+3.40%
CVAC CureVac	-0.19%	-0.92%	-0.74%	+18.54%	+67.29%
DRUG Bright Minds Biosciences	-1.68%	+1.19%	+22.43%	+63.96%	+3,775.45%
ELVN Enliven Therapeutics	-1.55%	+2.62%	+1.44%	+14.13%	-9.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	3.0984 of 5 stars	2.5	0.0	3.0	3.5	0.8	1.3
CVAC CureVac	4.5684 of 5 stars	3.1	5.0	4.9	4.0	0.0	1.3
DRUG Bright Minds Biosciences	2.4286 of 5 stars	3.6	2.0	0.0	2.8	2.5	0.0
ELVN Enliven Therapeutics	2.6183 of 5 stars	3.5	2.0	0.0	2.0	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	3.00	Buy	$42.33	9.11% Upside
CVAC CureVac	2.20	Hold	$6.83	27.25% Upside
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	114.12% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	103.26% Upside

Current Analyst Ratings Breakdown

Latest DRUG, ELVN, COLL, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	DRUG Bright Minds Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$85.00
8/11/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.94	$12.36 per share	3.14	$7.37 per share	5.26
CVAC CureVac	$510.51M	2.36	$0.87 per share	6.16	$2.97 per share	1.81
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$5.32 per share	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$8.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$69.19M	$1.04	37.31	6.45	N/A	5.13%	97.28%	13.87%	11/6/2025 (Estimated)
CVAC CureVac	$175.50M	$0.96	5.59	N/A	N/A	38.21%	29.57%	25.41%	11/11/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.93	N/A	N/A	N/A	N/A	-20.96%	-20.66%	N/A
ELVN Enliven Therapeutics	-$89.02M	-$2.00	N/A	N/A	N/A	N/A	-29.15%	-27.88%	11/12/2025 (Estimated)

Latest DRUG, ELVN, COLL, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	CVAC CureVac	-$0.15	-$0.30	-$0.15	-$0.30	$4.27 million	$1.41 million
8/14/2025	Q3 2025	DRUG Bright Minds Biosciences	-$0.59	-$0.53	+$0.06	-$0.53	N/A	N/A
8/13/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.27	1.18	1.10
CVAC CureVac	0.05	6.17	6.16
DRUG Bright Minds Biosciences	N/A	86.64	86.64
ELVN Enliven Therapeutics	N/A	32.58	32.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
CVAC CureVac	17.26%
DRUG Bright Minds Biosciences	40.52%
ELVN Enliven Therapeutics	95.08%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
CVAC CureVac	2.15%
DRUG Bright Minds Biosciences	42.66%
ELVN Enliven Therapeutics	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	31.50 million	30.71 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
ELVN Enliven Therapeutics	50	59.24 million	43.89 million	Optionable

DRUG, ELVN, COLL, and CVAC Headlines

Recent News About These Companies

Russell Investments Group Ltd. Boosts Stake in Enliven Therapeutics, Inc. $ELVN

August 28 at 3:37 AM | marketbeat.com

How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%

August 27 at 10:55 AM | zacks.com

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

August 25, 2025 | prnewswire.com

Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells 5,000 Shares of Stock

August 22, 2025 | insidertrades.com

Enliven Therapeutics (NASDAQ:ELVN) CEO Sells $11,800.00 in Stock

August 21, 2025 | insidertrades.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Lord Abbett & CO. LLC

August 19, 2025 | marketbeat.com

What is Lifesci Capital's Estimate for ELVN Q3 Earnings?

August 19, 2025 | marketbeat.com

Lifesci Capital Has Positive Outlook for ELVN Q3 Earnings

August 18, 2025 | americanbankingnews.com

Enliven Therapeutics (NASDAQ:ELVN) Announces Earnings Results

August 15, 2025 | marketbeat.com

We're Not Very Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn Rate

August 15, 2025 | finance.yahoo.com

Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

August 14, 2025 | finanznachrichten.de

Enliven Therapeutics Reports Positive Trial Results and Strong Financials

August 13, 2025 | tipranks.com

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

August 13, 2025 | prnewswire.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 6,667 Shares of Stock

August 12, 2025 | marketbeat.com

Enliven Therapeutics Inc. Stock Grades | ELVN | Barron's

August 12, 2025 | barrons.com

XTX Topco Ltd Takes $430,000 Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

August 10, 2025 | marketbeat.com

Federated Hermes Inc. Has $1.36 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

August 7, 2025 | marketbeat.com

Enliven Therapeutics (ELVN) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Buy" by Analysts

August 5, 2025 | marketbeat.com

19,386 Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Bought by BIT Capital GmbH

August 4, 2025 | marketbeat.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stock

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DRUG, ELVN, COLL, and CVAC Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$38.80 +0.45 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$38.78 -0.02 (-0.04%)

As of 05:38 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

CureVac NASDAQ:CVAC

$5.37 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$5.38 +0.00 (+0.09%)

As of 04:34 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Bright Minds Biosciences NASDAQ:DRUG

$38.88 -3.75 (-8.80%)

Closing price 04:00 PM Eastern

Extended Trading

$39.70 +0.82 (+2.11%)

As of 04:18 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Enliven Therapeutics NASDAQ:ELVN

$20.27 -0.09 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$20.27 0.00 (0.00%)

As of 04:20 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time